In mouse disease models, antibodies or small molecule antagonists of CXCR3 have been shown to significantly delay the progression of diseases such as atherosclerosis, transplant rejection, and cancer, making CXCR3 antagonists a key focus in drug discovery. Here, CXCR3 is linked to cancer.